hotspot -WSS

hotspot

author：hotspot 2025-08-12 09:12:30 - browse：663

Akero Therapeutics said Tuesday that an experimental medicine failed to show a significant benefit for patients with cirrhosis caused by NASH, the most advanced and life-threatening stage of the fatty liver disease.

While the study’s primary goal of improving liver fibrosis, or scarring, was not achieved, the Akero drug, called efruxifermin, outperformed placebo by 10 percentage points. The drug also resolved NASH symptoms, including reductions in liver fat and inflammation, and improved other markers of the disease.

“These are the best data reported to date for any NASH drug in this patient population,” said Kitty Yale, Akero’s chief development officer. “We missed the primary endpoint. We understand that, but there’s actually a lot of hope when you look at the totality of the data.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： The nurse manager staffing crisis is hurting patients

leisure time

WSS

First U.S. drug developed to treat liver disease MASH is approved

New Medicare drug pricing powers could soon be upended in court

Fauci’s Covid grilling leads GOP to weigh foreign research rules

New menopause drug shows promise in relief for hot flashes

Change Healthcare outage fallout shows need for new oversight

Change Healthcare outage fallout shows need for new oversight

Wikipedia

hotspot

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Heart disease and mental health: A look at cardiac psychology

In Memoriam: Notable people who died in 2023

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

The high cost of giving birth even with insurance

As AI in medicine takes off, can 'human in the loop' prevent harm?

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

In age of alternative facts, a scholarly course on calling out crap

The SUPPORT Act is critical to fighting the opioid crisis

focus

As JPM 2024 winds down, some health tech firms project optimism

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

DeSantis can now import cheaper drugs. But will Biden get credit?

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

GSK to buy asthma

The SUPPORT Act is critical to fighting the opioid crisis

leisure time

hotspot

focus

entertainment